Severe Impairment Battery Language scale: A language-assessment tool for Alzheimer's disease patients

Alzheimer's and Dementia

Volumn 5, Issue 5, 2009, Pages 375-379

  Ferris, Steven ^a   Ihl, Ralf ^b   Robert, Philippe ^c   Winblad, Bengt ^d   Gatz, Gudrun ^e   Tennigkeit, Frank ^e   Gauthier, Serge ^f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL OF NICE   (France)

^d KAROLINSKA INSTITUTE   (Sweden)

^e MERZ PHARMACEUTICALS GMBH   (Germany)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Clinical trial; Language; Scale; Severe Impairment Battery

Indexed keywords

DONEPEZIL; MEMANTINE; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COMMUNICATION DISORDER; CONTROLLED CLINICAL TRIAL; CORRELATION ANALYSIS; CRONBACH ALPHA COEFFICIENT; DATA BASE; FACTORIAL ANALYSIS; HUMAN; INTERNAL CONSISTENCY; LANGUAGE ABILITY; LANGUAGE DISABILITY; MEASUREMENT ERROR; MINI MENTAL STATE EXAMINATION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; RELIABILITY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEVERE IMPAIRMENT BATTERY LANGUAGE SCALE; SPEECH AND LANGUAGE ASSESSMENT; VARIANCE;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION DISORDERS; DISABILITY EVALUATION; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; LANGUAGE DISORDERS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOMETRICS; SEVERITY OF ILLNESS INDEX;

EID: 69949160876     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2009.04.1236     Document Type: Article

References (23)

1. Hendryx-Bedalov P.M. Alzheimer's dementia. Coping with communication decline. J Gerontol Nurs 15 (2000) 37-47
2. Ferrell B.A. Pain evaluation and management in the nursing home. Ann Intern Med 123 (1995) 681-687
3. Closs S.J., Barr B., and Briggs M. Cognitive status and analgesic provision in nursing home residents. Br J Gen Pract 54 (2004) 919-921
4. Zwakhalen S.M., Hamers J.P., Abu-Saad H.H., and Berger M.P. Pain in elderly with severe dementia: a systematic review of behavioral pain assessment tools. BMC Geriatr 6 (2006) 3
5. Tsai P.F., and Chang J.Y. Assessment of pain in elders with dementia. Med Surg Nurs 13 (2004) 364-369
6. Savundranayagam M.Y., Hummert M.L., and Montgomery R.J. Investigating the effects of communication problems on caregiver burden. J Gerontol [B] Psychol Sci Soc Sci 60 Suppl (2005) S48-S55
7. Boller F., Verny M., Hugonot-Diener L., and Saxton J. Clinical features and assessment of severe dementia. A review. Eur J Neurol 9 (2002) 125-136
8. Livingston G., Katona C., Francois C., Guilhaume C., Cochran J., and Sapin C. Characteristics and health status change over 6 months in people with moderately severe to severe Alzheimer's disease in the U.K. Int Psychogeriatr 18 (2006) 527-538
9. Carlomagno S., Pandolfi M., Marini A., Di Iasi G., and Cristilli C. Coverbal gestures in Alzheimer's type dementia. Cortex 41 (2005) 535-546
10. Bayles K., and Tomoeda C. Functional Linguistic Communication Inventory (1996), Canyonlands Publishing, Inc, Tucson, AZ
11. Saxton J., Swihart A.A., McGonigle-Gibson K.L., Miller V.J., and Boller F. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psychol Assess 2 (1990) 298-303
12. Saxton J., Kastango K.B., Hugonot-Diener L., Boller F., Verny M., Sarles C.E., et al. Development of a short form of the Severe Impairment Battery. Am J Geriatr Psychiatry 13 (2005) 999-1005
13. Panisset M., Roudier M., Saxton J., and Boller F. Severe Impairment Battery. A neuropsychological test for severely demented patients. Arch Neurol 51 (1994) 41-45
14. Schmitt F.A., Ashford W., Ernesto C., Saxton J., Schneider L.S., Clark C.M., et al. The Severe Impairment Battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. Alzheimer Dis Assoc Disord 11 (1997) 51-56
15. Homma A., Kitamura S., and Yoshimura I. Efficacy of Memantine in patients with moderately severe to severe Alzheimer's disease in Japan (dose-finding study). Eur J Neurol 14 Suppl 1 (2007) 49-50
16. van Dyck C.H., Tariot P.N., and Meyers B. Malca Resnick E. A 24-week randomized, controlled trial of Memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 14 (2007) 136-143
17. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial. JAMA 291 (2004) 317-324
18. Reisberg B., Doody R., Stöffler A., Schmitt F., Ferris S., and Möbius H.J. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348 (2003) 1333-1334
19. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
20. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 24 (1988) 653-659
21. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., and Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994) 2308-2314
22. Galasko D., Bennet D., Sano M., Ernesto C., Thomas R., Grundman M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 11 Suppl (1997) S33-S39
23. Beckerling A., Braun W., and Sommer M. Process of measuring in clinical medicine-implications of different definitions in clinical therapeutic studies. Digestion 70 (2004) 139-145